BioAge Labs (NASDAQ:BIOA) Earns “Buy” Rating from BTIG Research

BioAge Labs (NASDAQ:BIOA)‘s stock had its “buy” rating reissued by analysts at BTIG Research in a research note issued on Monday, Benzinga reports.

Other equities research analysts have also recently issued reports about the company. Weiss Ratings upgraded BioAge Labs from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, October 26th. Wall Street Zen lowered BioAge Labs from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 10th. Roth Capital reiterated a “buy” rating and issued a $25.00 target price on shares of BioAge Labs in a report on Wednesday, September 9th. Needham & Company LLC decreased their price target on shares of BioAge Labs from $50.00 to $35.00 and set a “buy” rating for the company in a research report on Friday, July 31st. Finally, Jefferies Financial Group set a $21.00 price target on shares of BioAge Labs in a report on Friday, July 31st. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, BioAge Labs presently has a consensus rating of “Moderate Buy” and an average price target of $33.00.

BioAge Labs Price Performance

BIOA stock opened at $5.34 on Monday. The business has a 50-day moving average price of $6.99 and a 200 day moving average price of $15.48. The company has a market capitalization of $245.11 million, a P/E ratio of -2.09 and a beta of 1.19. BioAge Labs has a 1-year low of $4.81 and a 1-year high of $25.95.

BioAge Labs (NASDAQ:BIOA) last issued its earnings results on Thursday, November 5th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.05). BioAge Labs had a negative return on equity of 31.42% and a negative net margin of 1,253.60%. The business had revenue of $0.30 million for the quarter. On average, analysts anticipate that BioAge Labs will post -2.49 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioAge Labs

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in shares of BioAge Labs in the second quarter valued at approximately $69,831,000. Jupiter Topco LLC purchased a new position in BioAge Labs during the second quarter worth approximately $52,597,000. Janus Henderson Group PLC lifted its position in BioAge Labs by 411.8% during the first quarter. Janus Henderson Group PLC now owns 2,094,270 shares of the company’s stock worth $36,597,000 after buying an additional 1,685,063 shares in the last quarter. Octagon Capital Advisors LP boosted its stake in BioAge Labs by 9.4% during the first quarter. Octagon Capital Advisors LP now owns 1,748,000 shares of the company’s stock worth $30,573,000 after buying an additional 150,000 shares during the last quarter. Finally, Walleye Capital LLC acquired a new position in BioAge Labs during the second quarter worth $8,686,000.

About BioAge Labs

BioAge Labs, Inc is a clinical-stage biotechnology company focused on developing medicines that target the biological mechanisms of aging. The company seeks to address diseases associated with aging by identifying therapeutic targets linked to human longevity and translating those discoveries into drug candidates.

BioAge uses large human data sets, computational biology, and machine-learning tools to study the molecular factors that influence healthy aging and age-related disease. Its research has produced a pipeline of investigational therapies, including azelaprag (BGE-105), an apelin receptor agonist being evaluated for potential applications involving metabolic health, body composition, and physical function.

Founded in 2015, BioAge is headquartered in Richmond, California, and conducts research and clinical development activities through collaborations and studies involving patients and research sites in multiple regions.